Brian Park, PharmD

Drug Information Specialist https://www.rheumatologyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

General Rheumatology

Abbott’s 15-Minute COVID-19 Antigen Test Gets Emergency Use Authorization

Brian Park, PharmD

September 1, 2020

The FDA issued an Emergency Use Authorization for BinaxNOW™ COVID-19 Ag Card a rapid antigen test for the detection of COVID-19.

Spondyloarthritis

Upadacitinib Application for Ankylosing Spondylitis Submitted for Review

Brian Park, PharmD

August 28, 2020

The application is supported by data from the multicenter, double-blind, placebo-controlled phase 2/3 SELECT-AXIS 1 study.

General Rheumatology

Trial Evaluating Monoclonal Antibody Combination for COVID-19 Begins

Brian Park, PharmD

August 28, 2020

A phase 1 study of AstraZeneca’s investigational monoclonal antibody AZD7442 for COVID-19 has been initiated.

Pain Management

Orphenadrine and Aspirin Combination Now Available for Pain Management

Brian Park, PharmD

August 27, 2020

Orphengesic Forte for the symptomatic relief of mild to moderate pain of acute musculoskeletal disorders is now available.

Practice Management

HHS Authorizes Pharmacists to Administer Vaccines to Children

Brian Park, PharmD

August 26, 2020

HHS issued the amendment in order to increase access to childhood vaccines and decrease the risk of vaccine-preventable disease outbreaks as children return to daycare and school.

General Rheumatology

Novavax’s Adjuvanted COVID-19 Vaccine Candidate Shows Promise in Early Trial

Brian Park, PharmD

August 12, 2020

Novavax announced positive phase 1 data of its COVID-19 vaccine candidate, NVX-CoV2373.

General Rheumatology

No Benefit Observed With Tocilizumab in COVID-19 Pneumonia Trial

Brian Park, PharmD

August 10, 2020

A phase 3 study of tocilizumab for the treatment of hospitalized patients with severe COVID-19 pneumonia did not meet its primary and key secondary end points.

Systemic Lupus Erythematosus

Voclosporin Granted Priority Review for Lupus Nephritis

Brian Park, PharmD

July 29, 2020

The FDA will give Priority Review to the New Drug Application (NDA) of voclosporin for the treatment of lupus nephritis.

General Rheumatology

Early Data Show Investigational ChAdOx1 nCoV-19 Vaccine Safe, Immunogenic

Brian Park, PharmD

July 24, 2020

Interim results from the phase 1/2 COV001 trial evaluating the vaccine candidate ChAdOx1 nCoV-19 (AZD1222) showed that vaccination led to strong immune responses.

Pain Management

FDA Approves Orphenadrine and Aspirin Combination for Pain Management

Brian Park, PharmD

July 23, 2020

The FDA has approved the supplemental Abbreviated New Drug Application (sANDA) for Orphengesic Forte.

Next post in Pain Management